| 5.29 0.45 (9.3%) | 11-17 13:22 | |||||||||||||
|
|
| Short term | ||||
| Mid term | |
|||
| Targets | 6-month : | 8.44 |
1-year : | 10.51 |
| Resists | First : | 7.23 |
Second : | 9 |
| Pivot price | 7.07 |
|||
| Supports | First : | 4.36 | Second : | 3.63 |
| MAs | MA(5) : | 5.68 |
MA(20) : | 7.16 |
| MA(100) : | 8.41 |
MA(250) : | 7.27 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 16.5 |
D(3) : | 17 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 12.69 | Low : | 4.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ECOR ] has closed above bottom band by 14.7%. Bollinger Bands are 55.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.76 - 5.8 | 5.8 - 5.83 |
| Low: | 4.64 - 4.69 | 4.69 - 4.72 |
| Close: | 4.78 - 4.84 | 4.84 - 4.89 |
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Mon, 16 Nov 2026
Director buys 10,000 electroCore (ECOR) shares at a $5.44 average price. - Stock Titan
Mon, 09 Nov 2026
electroCore (ECOR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Wed, 04 Nov 2026
Sales rose 12% at electroCore (ECOR), but its cash outlook brings a warning. - Stock Titan
Wed, 04 Nov 2026
electroCore, Inc. (ECOR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 29 Oct 2026
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026 - GlobeNewswire
Thu, 08 Oct 2026
When Can We Expect A Profit From electroCore, Inc. (NASDAQ:ECOR)? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 34.1 (%) |
| Held by Institutions | 11.9 (%) |
| Shares Short | 348 (K) |
| Shares Short P.Month | 322 (K) |
| EPS | -1.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.21 |
| Profit Margin | -40 % |
| Operating Margin | -29.4 % |
| Return on Assets (ttm) | -55 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 28 % |
| Gross Profit (p.s.) | 3.48 |
| Sales Per Share | 4 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -3.92 |
| PEG Ratio | 0 |
| Price to Book value | -25.34 |
| Price to Sales | 1.32 |
| Price to Cash Flow | -5.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |